Skip to main content
Erschienen in: Familial Cancer 1/2012

01.03.2012 | Original Article

Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London

verfasst von: Kelly Kohut, Lucia D’Mello, Elizabeth K. Bancroft, Sarah Thomas, Mary-Anne Young, Kathryn Myhill, Susan Shanley, Brian H. J. Briggs, Michelle Newman, Ifthikhar M. Saraf, Penny Cox, Sarah Scambler, Lyndon Wagman, Michael T. Wyndham, Rosalind A. Eeles, Michelle Ferris

Erschienen in: Familial Cancer | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

At present cancer genetics referrals are reactive to individuals asking for a referral and providing a family history thereafter. A previous pilot study in a single General Practice (GP) catchment area in North London showed a 1.5-fold increase in breast cancer risk in the Ashkenazi Jewish population compared with the non-Ashkenazi mixed population. The breast cancer incidence was equal in the Ashkenazim in both pre- and postmenopausal groups. We wanted to investigate the effect of proactively seeking family history data from the entire female population of the practice to determine the effect on cancer genetics referral. Objectives To determine the need for cancer genetics intervention for women in a single GP catchment area. (1) to determine the incidence and strength of family history of cancer in women aged over 18 in the practice, (2) to offer cancer genetics advice and determine the uptake of counselling in those with a positive family history, (3) to identify potential BRCA1/BRCA2 gene mutation carriers who can be offered clinical follow up with appropriate translational research studies. Design Population-based cohort study of one General Practice female population. Participants Three hundred and eighty-three women over the age of 18 from one General Practice who responded to a questionnaire about family history of cancer. The whole female adult GP population was the target and the total number sampled was 3,820. Results 10% of patients completed the questionnaire (n = 383). A family history of cancer was present in 338 cases, 95 went on to have genetic counselling or had previously had counselling and 47 were genetically tested. We identified three carriers of an Ashkenazi Jewish founder mutation in BRCA1. Conclusions Response rate to a family history questionnaire such as that used in genetics centres was low (10%) and other approaches will be needed to proactively assess family history. Although the Ashkenazim are present in 39% of the GP catchment area, 62% of those who returned a family history questionnaire were from this ethnic group and of those returned, 44% warranted referral to a cancer genetics unit. In the non Ashkenazim, the questionnaire return rate was 38% and 18% of those warranted referral to cancer genetics.
Literatur
1.
Zurück zum Zitat Antoniou AC, Pharoah PDP, Narod S et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42:602–603PubMedCrossRef Antoniou AC, Pharoah PDP, Narod S et al (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42:602–603PubMedCrossRef
2.
Zurück zum Zitat Antoniou AC, Cunningham AP, Peto J et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98:1457–1466PubMedCrossRef Antoniou AC, Cunningham AP, Peto J et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98:1457–1466PubMedCrossRef
3.
Zurück zum Zitat The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. JNCI 9115:1310–1316 The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. JNCI 9115:1310–1316
4.
Zurück zum Zitat Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7(3):223–229PubMedCrossRef Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7(3):223–229PubMedCrossRef
5.
Zurück zum Zitat Ferris M, Easton D, Doherty R et al (2007) A population-based audit of ethnicity and breast cancer risk in one General Practice catchment area in North London, UK: implications for practice. Hered Cancer Clin Pract 5(3):157–160PubMedCrossRef Ferris M, Easton D, Doherty R et al (2007) A population-based audit of ethnicity and breast cancer risk in one General Practice catchment area in North London, UK: implications for practice. Hered Cancer Clin Pract 5(3):157–160PubMedCrossRef
6.
Zurück zum Zitat Grann VR, Jacobson JS, Thomason D et al (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20:2520–2529PubMedCrossRef Grann VR, Jacobson JS, Thomason D et al (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20:2520–2529PubMedCrossRef
7.
Zurück zum Zitat Hartge P, Struewing JP, Wacholder S et al (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Human Genet 64:963–970CrossRef Hartge P, Struewing JP, Wacholder S et al (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Human Genet 64:963–970CrossRef
8.
Zurück zum Zitat Metcalfe KA, Poll A, Royer R et al (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28:387–391PubMedCrossRef Metcalfe KA, Poll A, Royer R et al (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28:387–391PubMedCrossRef
9.
Zurück zum Zitat Rubenstein WS, Jiang H, Dellafave L et al (2009) Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for diaglogue. Genet Med 22:629–639CrossRef Rubenstein WS, Jiang H, Dellafave L et al (2009) Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for diaglogue. Genet Med 22:629–639CrossRef
10.
Zurück zum Zitat Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRef Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRef
11.
Zurück zum Zitat Thompson D, Easton DF (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Human Genet 68:410–419CrossRef Thompson D, Easton DF (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Human Genet 68:410–419CrossRef
12.
Zurück zum Zitat Tonin P, Weber B, Offit K et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179–1183PubMedCrossRef Tonin P, Weber B, Offit K et al (1996) Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179–1183PubMedCrossRef
Metadaten
Titel
Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London
verfasst von
Kelly Kohut
Lucia D’Mello
Elizabeth K. Bancroft
Sarah Thomas
Mary-Anne Young
Kathryn Myhill
Susan Shanley
Brian H. J. Briggs
Michelle Newman
Ifthikhar M. Saraf
Penny Cox
Sarah Scambler
Lyndon Wagman
Michael T. Wyndham
Rosalind A. Eeles
Michelle Ferris
Publikationsdatum
01.03.2012
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 1/2012
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9482-6

Weitere Artikel der Ausgabe 1/2012

Familial Cancer 1/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.